Fernández-Brando Romina J, Bentancor Leticia V, Mejías María Pilar, Panek Analía C, Cabrera Gabriel G, Exeni Ramón A, Palermo Marina S
División Inmunología, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina.
Medicina (B Aires). 2011;71(4):383-9.
The typical form of hemolytic uremic syndrome (HUS) is the major complication of Shiga toxin-producing Escherichia coli (STEC) infections. HUS is a critical health problem in Argentina since it is the main cause of acute renal failure in children and the second cause of chronic renal failure, giving account for 20% of renal transplants in children and adolescents in our country. In spite of the extensive research in the field, the mainstay of treatment for patients with HUS is supportive therapy, and there are no specific therapies preventing or ameliorating the disease course. In this review, we present the current knowledge about pathogenic mechanisms and discuss traditional and innovative therapeutic approaches, with special focus in national status and contributions made by Argentinean groups.
溶血性尿毒症综合征（HUS）的典型形式是产志贺毒素大肠杆菌（STEC）感染的主要并发症。HUS在阿根廷是一个严重的健康问题，因为它是儿童急性肾衰竭的主要原因以及慢性肾衰竭的第二大原因，占我国儿童和青少年肾移植的20%。尽管该领域进行了广泛研究，但HUS患者的主要治疗方法仍是支持性治疗，尚无预防或改善病程的特异性疗法。在本综述中，我们介绍了关于致病机制的现有知识，并讨论了传统和创新的治疗方法，特别关注阿根廷研究团队的国内现状和贡献。
